Login / Signup

Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes.

Nathaniel A CohenJoshua M SteinbergAlexa SilfenCindy TraboulsiTina G RodriguezJorie M SingerShivani PatelRussell D CohenSushila R DalalAtsushi SakurabaJoel PekowDejan MicicDavid T Rubin
Published in: Digestive diseases and sciences (2022)
This study demonstrates the effectiveness and long-term safety of tofacitinib in patients with UC. Importantly, we show that the endpoint of endo-histologic healing is achievable with tofacitinib and can occur as early as week 8 of therapy.
Keyphrases
  • rheumatoid arthritis
  • ulcerative colitis
  • randomized controlled trial
  • systematic review
  • clinical trial
  • bone marrow
  • mesenchymal stem cells